ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

ATHE Alterity Therapeutics Limited

2.19
-0.005 (-0.23%)
Pre Mercado
Última actualización: 05:36:34
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Alterity Therapeutics Limited ATHE NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.005 -0.23% 2.19 05:36:34
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.195
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202406:25GLOBEAppendix 4C – Q3 FY24 Quarterly Cash Flow Report
29/4/202406:25GLOBEAlterity Therapeutics Presents New Data Demonstrating..
17/4/202406:25GLOBEAlterity Therapeutics Parkinson’s Disease and Multiple..
10/4/202406:25GLOBEAlterity Therapeutics to Present New Data on ATH434 at the..
26/3/202409:25GLOBEAlterity Therapeutics Receives a A$3.9 Million Research &..
20/2/202409:25GLOBEAlterity Therapeutics to Present New Data at the Upcoming..
15/2/202416:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/2/202416:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/2/202406:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
31/1/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/1/202406:24GLOBEAlterity Therapeutics to Participate in the ShareCafe Hidden..
22/1/202406:25GLOBEAlterity Therapeutics Issues Shareholder Letter Highlighting..
22/1/202405:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/1/202416:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/1/202416:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/1/202405:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202407:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202407:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202407:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202405:27EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/1/202405:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/1/202407:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/1/202407:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/1/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/12/202307:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/12/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202307:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202323:30GLOBEAlterity Therapeutics Appoints Phillip Hains as Chief..
04/12/202315:35GLOBEAlterity Therapeutics to Host Webcast to Discuss ATH434..
04/12/202306:25GLOBEAlterity Therapeutics Reports Positive Efficacy Data for..
27/11/202306:25GLOBEAlterity Therapeutics Announces Presentation of Novel..
16/11/202306:25GLOBEAlterity Therapeutics Announces Presentation of New Data..
08/11/202306:25GLOBEAlterity Therapeutics Completes Enrolment in ATH434-201..
30/10/202306:25GLOBEAppendix 4C – Q1 FY24 Quarterly Cash Flow Report
25/10/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
13/9/202305:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/8/202306:25GLOBEAlterity Therapeutics Presents New Data on Multiple System..
23/8/202306:25GLOBEAlterity Therapeutics Granted New Composition of Matter..
22/8/202306:25GLOBEAlterity Therapeutics Rare Disease Natural History Study to..
15/8/202306:25GLOBEAlterity Therapeutics Receives a $4.74 million Research &..
31/7/202306:52GLOBEAppendix 4C – Q4 FY23 Quarterly Cash Flow Report
26/7/202306:25GLOBEAlterity Therapeutics Phase 2 Data Monitoring Committee..
21/6/202306:25GLOBEAlterity Therapeutics to Present in MST Access Rare..
30/5/202306:25GLOBEAlterity Therapeutics Initiates Second Phase 2 Study in Rare..
19/5/202306:25GLOBEAlterity Therapeutics CEO David Stamler to Present at the..
10/5/202306:25GLOBEAppendix 4C – Q3 FY23 Quarterly Cash Flow Report

Su Consulta Reciente

Delayed Upgrade Clock